Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25-Reference-Cited by-同舟云学术

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Published:2015-01-13 Issue:2 Volume:25 Page:208-224
ISSN:1001-0602
Container-title:Cell Research
language:en
Short-container-title:Cell Res

Author:

Hannani Dalil,Vétizou Marie,Enot David,Rusakiewicz Sylvie,Chaput Nathalie,Klatzmann David,Desbois Melanie,Jacquelot Nicolas,Vimond Nadège,Chouaib Salem,Mateus Christine,Allison James P,Ribas Antoni,Wolchok Jedd D,Yuan Jianda,Wong Philip,Postow Michael,Mackiewicz Andrzej,Mackiewicz Jacek,Schadendorff Dirk,Jaeger Dirk,Korman Alan J,Bahjat Keith,Maio Michele,Calabro Luana,Teng Michele WL,Smyth Mark J,Eggermont Alexander,Robert Caroline,Kroemer Guido,Zitvogel Laurence

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/cr20153.pdf

Reference61 articles.

1. Schreiber RD, Old LJ, Smyth MJ . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565–1570.

2. Fridman WH, Pages F, Sautes-Fridman C, Galon J . The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298–306.

3. Bour-Jordan H, Esensten JH, Martinez-Llordella M, et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev 2011; 241:180–205.

4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–723.

5. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517–2526.

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy;Cancers;2024-03-21

2. Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A;Cancers;2024-03-04

3. Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?;The Cancer Journal;2024-03

4. Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application;Interdisciplinary Medicine;2024-01

5. The soluble IL‐2 receptor α/CD25 as a modulator of IL‐2 function;Immunology;2023-11-30